Baroda BNP Paribas Mutual Fund logo

Baroda BNP Paribas Health and Wellness Fund Regular Growth NAV today

AMFI: 153602ISIN: INF251K01UY7MUTF_IN: BARO_BNP_P_3QYJSPBaroda BNP Paribas Mutual FundSectoral / Thematic funds

NAV ₹9.9298down ₹0.10 (0.95%)

NAV for 23 Oct 2026, against 22 Oct 2026. Declared once a day.

Fund size
₹487 CrSep 2026
Expense ratio
2.70%16 Oct 2026
P/E
39.330 Sep 2026
Risk level
Very HighAug 2026
Holdings
3330 Sep 2026
Launched
27 Jun 2025

Baroda BNP Paribas Health and Wellness Fund returns

Regular Growth plan

Over each window to 23 Oct 2026

OverReturnBenchmarkRank in categoryCategory medianMiddle half
1 week−2.05%––––
1 month−8.97%–158 of 254−8.33%−9.6% to −6.7%
3 months−5.24%–84 of 249−6.53%−8.0% to −4.6%
6 months+5.93%–38 of 249−4.08%−6.9% to +1.7%
1 year+0.83%+16.77%to 30 Sep 202650 of 228−6.21%−10.1% to −0.6%
3 yearsNeeds 3 years––+10.84%+7.2% to +15.3%
5 yearsNeeds 5 years––+9.47%+6.9% to +13.1%
10 yearsNeeds 10 years––+12.66%+10.6% to +14.0%
₹10,000 put in on 1 Jul 2025 is ₹9,920 at the NAV of 23 Oct 2026Over a year and longer, a return is the yearly rate. Benchmark: BSE Healthcare TRI, over the same days as the fund, or to the month end its cell names. Rank, median and middle half among the Regular plans of Sectoral / Thematic funds, each fund's return to its latest NAV on or before 25 Oct 2026.

At the month end, 30 Sep 2026

OverFundBenchmark
1 year+10.84%+16.77%
Since launch+3.75%+11.41%
Benchmark: BSE Healthcare TRI. Both as the fund house states them for the month.

Baroda BNP Paribas Health and Wellness Fund SIP returns

₹10,000 on the 1st of every month, valued at the NAV of 23 Oct 2026

PeriodInvestedValue todayInvested against value todaySIP returnAfter stamp dutyStamp duty
1 year12 instalments₹1,20,000₹1,21,434₹1,21,428 after stamp duty+2.32%+2.31%₹6
Since Jul 202516 instalments₹1,60,000₹1,62,079₹1,62,071 after stamp duty+1.90%+1.89%₹8

3 years: Launched 27 Jun 2025, needs 3 years of history.

Baroda BNP Paribas Health and Wellness Fund expense ratio and exit load

Per cent of the money invested, a year. Each month shows its last day filed; the parts were redefined from Apr 2026.

Regular over direct
1.23 ptsA year, on 16 Oct 2026
Direct, 30-day average
1.49%Over the last 30 days filed
Regular, 30-day average
2.72%Over the last 30 days filed

Total expense ratio, month by month

  • Regular plan
  • Direct plan
Direct plan highest 1.56%, Aug 2026.Direct plan lowest 0.43%, Nov 2025.

What the expense ratio is made of

PartDirectRegular
Base expense ratio1.04%2.09%
Brokerage0.08%0.08%
Transaction costsNoneNone
Statutory levies0.35%0.53%
Per cent of assets a year, filed for 23 Oct 2026. The parts add up to that day's total.

Exit load, in the fund house's words

Redemption/ switch out of units upto 10% of the units allotted before 1 year from date of allotment- Exit load -NIL For redemption/switch out of units above 10% of units allotted within 1 year from the date of allotment- 1.00% of applicable NAV For redemption/switch out of units after 1 year from the date of allotment-NilMoreLess

Buying and selling

Lump-sum purchases
Accepted
Minimum investment
₹1,000
Minimum top-up
₹1,000
Minimum redemption
₹1,000
SIP
Accepted
STP, transfers to another fund
Not accepted
SWP, regular withdrawals
Accepted
Switches
Accepted
Lock-in
None
SIP minimum
500 for daily, weekly & monthly and 1500 for quarterly
As listed for this plan on 24 Oct 2026.

Baroda BNP Paribas Health and Wellness Fund AUM

₹ crore, every plan of the fund together.

Average assets
₹511 CrQuarter to Sep 2026
In the direct plans
2.0%Of the quarter's average

Average assets by quarter, by plan

  • Regular plans
  • Direct plans
Largest ₹650 Cr, quarter to Sep 2025.

Assets at each month end

Highest ₹638 Cr, Aug 2025.The latest month end is the lowest since Aug 2025.

Baroda BNP Paribas Health and Wellness Fund portfolio

Portfolio disclosed for 30 Sep 2026.

Holdings on 30 Sep 2026

Sun Pharmaceutical IndustriesPharmaceuticals & BiotechnologyLarge cap13th8.58%41.832,30,250Jun 2025or earlier
Torrent PharmaceuticalsPharmaceuticals & BiotechnologyLarge cap61st7.88%38.4080,000Jun 2025or earlier
Divi's LaboratoriesPharmaceuticals & BiotechnologyLarge cap50th7.82%38.1041,000Jun 2025or earlier
IPCA LaboratoriesPharmaceuticals & BiotechnologyMid cap229th6.13%29.871,55,000Jul 2025
Laurus LabsPharmaceuticals & BiotechnologyMid cap171st6.09%29.701,50,000Nov 2025
LupinPharmaceuticals & BiotechnologyMid cap105th5.79%28.221,39,000Jul 2025
Apollo Hospitals EnterpriseHealthcare ServicesLarge cap97th5.28%25.7231,500Jun 2025or earlier
Fortis HealthcareHealthcare ServicesMid cap156th3.98%19.402,52,000Jun 2025or earlier
Dr. Lal Path LabsHealthcare ServicesSmall cap309th3.47%16.8985,000Jul 2025
Mankind PharmaPharmaceuticals & BiotechnologyMid cap119th3.34%16.2765,000Jul 2025
Glenmark PharmaceuticalsPharmaceuticals & BiotechnologyMid cap176th3.11%15.1865,000Mar 2026
Aurobindo PharmaPharmaceuticals & BiotechnologyMid cap138th3.09%15.0590,000Mar 2026
AstraZeneca Pharma IndiaPharmaceuticals & BiotechnologySmall cap333rd2.79%13.6122,000Jun 2025or earlier
Abbott IndiaPharmaceuticals & BiotechnologyMid cap183rd2.50%12.214,500Jun 2025or earlier
Emcure PharmaceuticalsPharmaceuticals & BiotechnologySmall cap266th2.39%11.6660,000Nov 2025
Weight is per cent of the fund's net assets; value in ₹ crore.
Largest holding
8.58%Sun Pharmaceutical Industries
Top 5 holdings
36.50%
Top 10 holdings
58.36%
Effective holdings
20.8Taken over 97.06% of the fund

Asset allocation

  • Indian shares97.06%
  • Cash and receivables2.94%
Per cent of the fund's net assets.

Large, mid and small cap

  • Large cap32.07%Category 49.50%
  • Mid cap46.47%Category 21.62%
  • Small cap18.68%Category 26.68%
Per cent of the fund's Indian shares. By the list for the six months to Jun 2026. Shares not on the list: 2.70% of the fund. Category is the average of 249 Sectoral / Thematic funds.

Sector allocation

3sectors
  • Healthcare93.48%Category 12.70%
  • Financial Services2.68%Category 21.68%
  • Information Technology0.90%Category 5.12%
Per cent of the fund's net assets, less the futures sold on its shares, Sep 2026. Category is the average of 254 Sectoral / Thematic funds.

Sector allocation month by month

13 months
Healthcare30 companies93.48%94.09%91.83%89.90%86.95%86.77%86.68%86.35%89.91%90.27%92.12%91.36%
Financial Services2 companies2.68%2.91%2.27%5.44%7.27%7.29%6.32%6.97%3.94%3.30%2.94%2.76%
Information Technology1 company0.90%0.85%1.42%1.52%1.54%1.56%1.29%1.10%1.14%0.00%0.00%0.00%
Capital Goods0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Automobile And Auto Components0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Consumer Services0.00%0.93%1.09%1.17%1.65%1.64%1.63%1.39%1.91%1.79%1.72%1.41%
Fast Moving Consumer Goods0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Consumer Durables0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Oil Gas & Consumable Fuels0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Telecommunication0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Power0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Services0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Per cent of the fund's net assets, less the futures sold on its shares, at each month end, Oct 2025 to Sep 2026; the line runs from Sep 2025.

Bought and sold

Sep 2026 against Aug 2026, position by position.

Positions changed, month by month

  • New
  • Added
  • Trimmed
  • Sold out
New positions
10.97% of the fund
Sold out
10.93% of the fund before
Added to
2
Trimmed
8
Unchanged
22
Traded at least
0.93%
Weight that moved
4.71%

Changes in Sep 2026

Narayana HrudayalayaNew0.97%0.00%+0.97 pts+26,500
Medplus Health ServicesSold out–0.93%−0.93 pts−70,000
AstraZeneca Pharma IndiaTrimmed2.79%3.56%−0.77 pts−4,000
Procter & Gamble HealthTrimmed0.17%0.57%−0.40 pts−3,467
Glenmark PharmaceuticalsTrimmed3.11%3.42%−0.31 pts−5,000
Divi's LaboratoriesTrimmed7.82%8.01%−0.19 pts−1,925
Apollo Hospitals EnterpriseAdded5.28%5.44%−0.16 pts+500
Metropolis HealthcareTrimmed1.33%1.49%−0.16 pts−10,000
Acutaas ChemicalsTrimmed2.36%2.24%+0.12 pts−1,040
IPCA LaboratoriesTrimmed6.13%6.23%−0.10 pts−5,000
Nephrocare Health ServicesAdded1.42%1.35%+0.07 pts+5,000
Emcure PharmaceuticalsTrimmed2.39%2.38%+0.01 pts−5,110
Weights are per cent of the fund's net assets; a change in weight is in percentage points.

Holdings month by month

HoldingOct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
Sun Pharmaceutical Industries9.25%Cut8.99%Cut7.17%Cut8.49%Added9.23%Added10.23%9.38%Cut9.09%7.58%Cut8.82%Added9.01%8.58%
Torrent Pharmaceuticals3.73%3.96%4.26%4.73%4.99%5.32%5.13%5.27%5.43%8.58%Added7.99%Cut7.88%
Divi's Laboratories7.05%Cut4.24%Cut4.35%1.88%Cut1.92%1.95%2.07%3.68%Added5.35%Added6.66%Cut8.01%7.82%Cut
IPCA Laboratories2.65%3.47%Added3.53%3.94%3.95%5.28%Added5.34%Added5.18%5.80%Added5.72%Cut6.23%Cut6.13%Cut
Laurus Labs–1.27%Bought again2.83%Added2.83%Added4.09%Added4.43%Added4.78%5.76%6.31%5.24%Cut5.66%6.09%
Lupin1.90%3.07%Added4.49%Added4.94%5.71%Added6.29%6.09%5.83%6.56%Added6.46%Cut5.99%5.79%
Apollo Hospitals Enterprise6.18%6.00%4.80%Cut3.83%Cut4.15%3.24%Cut4.32%Added4.66%Added4.87%5.35%5.44%5.28%Added
Fortis Healthcare1.65%1.50%3.01%Added3.13%4.59%Added3.09%Cut4.35%Added4.27%4.32%4.55%4.50%Added3.98%
Dr. Lal Path Labs2.02%Added2.50%Added2.52%2.59%2.48%2.55%2.58%2.51%Cut2.53%3.12%3.24%3.47%
Mankind Pharma7.29%7.00%7.11%7.41%1.19%Cut1.17%1.27%0.03%Cut2.99%Added3.09%3.10%3.34%
Glenmark Pharmaceuticals–––––1.24%Bought2.72%Added2.61%Added3.19%Added3.44%3.42%Cut3.11%Cut
Aurobindo Pharma–––––2.53%Bought again2.62%2.62%2.85%3.04%3.05%Cut3.09%
AstraZeneca Pharma India4.00%Added3.84%4.00%4.08%4.07%3.92%4.03%4.12%3.87%4.05%3.56%2.79%Cut
Abbott India4.57%Added4.82%4.84%4.96%4.60%5.53%Added5.28%5.43%2.07%Cut2.41%2.29%2.50%
Emcure Pharmaceuticals–0.57%Bought1.74%Added2.69%Added2.80%Added3.36%3.44%3.38%3.60%2.46%Cut2.38%2.39%Cut
Per cent of the fund's net assets at each month end, Oct 2025 to Sep 2026. Under it, the change on the fund's previous month. "After a gap" is a holding after a month with no portfolio on record, so when it was bought is not known; "Not filed" is one gone across such a gap.

Portfolio turnover, per cent of assets a year

  • Turnover
Highest 86.0% in Jun 2026

Risk ratios

NAV to 23 Oct 2026

Each bar runs from the lowest to the highest figure among the Regular plans of Sectoral / Thematic funds (227 funds) over the same 1 year; the tick is their average and the dot this fund.

How much the NAV moves

Standard deviation13.32%
12.43%Lowest20.05%Average46.92%Highest
Downside deviation8.17%
4.45%Lowest13.49%Average21.72%Highest
Sharpe ratio0.44
−1.33Lowest0.01Average1.81Highest
Sortino ratio0.65
−1.46Lowest0.10Average4.21Highest

Against BSE Healthcare TRI

Beta0.85
0.55Lowest0.97Average of 218 funds1.46Highest
R-squared92.1
27.0Lowest89.5Average of 218 funds99.3Highest
Correlation0.96
0.52Lowest0.94Average of 218 funds1.00Highest
Upside capture82.1%
57.0%Lowest104.4%Average of 185 funds178.4%Highest
Downside captureNeeds 6 falling months
Information ratioTo 30 Sep 2026−1.33

Largest falls

Largest overFallHigh onLow onBack at the high
1 year−9.02%23 Oct 20252 Apr 20268 May 2026
Since Jul 2025−11.93%30 Jul 20252 Apr 202629 Jun 2026

Risk level by month

MonthsFundBenchmark
Jul 2025 to Aug 202614 monthsVery HighVery HighBSE Healthcare TRI
The riskometer at each month end, the fund's and its benchmark's. A month with none on record is left out.

Baroda BNP Paribas Health and Wellness Fund managers

Managers now

Manager
Rohan KordePrimaryMay 2026+5.23%over 165 days––21.5%26.7%9₹9,991 Cr
Ankeet PandyaPrimaryJul 2026−3.49%over 98 days––15.0%21.3%6₹8,691 Cr
Returns are the regular plan's growth NAV, from the day each took over to the latest NAV, beside the benchmark over the same days.

Other funds they run

Fund
Baroda BNP Paribas Multi Cap FundRohan KordeJul 2026−3.14%over 107 days−2.96%−0.18 pts₹3,297 Cr
Baroda BNP Paribas Mid Cap FundRohan KordeMay 2026−2.37%over 165 days−1.55%−0.82 pts₹2,503 Cr
Baroda BNP Paribas Value FundRohan KordeJul 2026−4.00%over 107 days−3.33%−0.67 pts₹920 Cr
Baroda BNP Paribas Business Conglomerates FundRohan KordeJul 2026−4.03%over 107 days−3.53%−0.50 pts₹579 Cr
Baroda BNP Paribas Services FundRohan KordeAug 2026−4.59%over 72 days−3.30%−1.29 pts₹573 Cr
Baroda BNP Paribas ESG Best-in-Class Strategy FundRohan KordeJul 2026−2.68%over 107 days−1.42%−1.26 pts₹564 Cr
Baroda BNP Paribas Business Cycle FundRohan KordeJul 2026−1.80%over 107 days––₹535 Cr
Baroda BNP Paribas Dividend Yield FundRohan KordeJul 2026−2.23%over 107 days−3.33%+1.10 pts₹532 Cr
Baroda BNP Paribas Multi Cap FundAnkeet PandyaJul 2026−3.14%over 107 days−2.96%−0.18 pts₹3,297 Cr
Baroda BNP Paribas Mid Cap FundAnkeet PandyaJul 2026−5.57%over 107 days−4.54%−1.03 pts₹2,503 Cr
Up to ten funds a manager, largest first. Returns are the regular plan's.

Portfolio overlap

Funds holding the most of the same securities, by weight.

Closest funds in the category

Mirae Asset Healthcare FundMirae Asset Mutual Fund61.10%18
Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund55.08%20
ITI Pharma and Healthcare FundITI Mutual Fund54.03%19
LIC Mf Healthcare FundLIC Mutual Fund50.96%14
SBI Healthcare Opportunities FundSBI Mutual Fund49.92%17
PGIM India Healthcare FundPGIM India Mutual Fund49.27%16
Bajaj Finserv Healthcare FundBajaj Finserv Mutual Fund49.14%15
Nippon India Pharma FundNippon India Mutual Fund48.55%19
WhiteOak Capital Pharma and Healthcare FundWhiteOak Capital Mutual Fund48.24%19
Kotak Healthcare FundKotak Mahindra Mutual Fund45.74%17
Portfolios for Sep 2026. Overlap is per cent of the portfolio the two funds hold in common.

Overlap with the fund house's other funds

Baroda BNP Paribas Manufacturing FundBaroda BNP Paribas Mutual Fund16.37%
Baroda BNP Paribas Small Cap FundBaroda BNP Paribas Mutual Fund15.26%
Baroda BNP Paribas Innovation FundBaroda BNP Paribas Mutual Fund14.62%
Baroda BNP Paribas Mid Cap FundBaroda BNP Paribas Mutual Fund13.02%
Baroda BNP Paribas Value FundBaroda BNP Paribas Mutual Fund11.70%
Baroda BNP Paribas Dividend Yield FundBaroda BNP Paribas Mutual Fund10.44%
Baroda BNP Paribas Multi Cap FundBaroda BNP Paribas Mutual Fund9.68%
Baroda BNP Paribas Business Cycle FundBaroda BNP Paribas Mutual Fund8.48%
Baroda BNP Paribas Flexi Cap FundBaroda BNP Paribas Mutual Fund8.23%
Baroda BNP Paribas Large Cap FundBaroda BNP Paribas Mutual Fund6.80%
As the fund house states it, for Sep 2026.

Changes to the fund

Newest first.

  1. 2026

    • 12 AugExpenseBase expense ratio, direct plan: 0.61% to 1.04%+0.43 pts
    • 1 AprExpenseExpense ratio stated under the new rules: a base ratio, with brokerage, levies and GST on top

Fund details

Objective

The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.

Asset allocation

  • Equity & equity related instruments of companies in the Pharma & Healthcare and allied sector- 80-100%
  • Equity and equity related instruments of companies other than above- 0-20%
  • Money Market and other liquid instruments*, Gold and Silver instruments (through ETFs) - 0-20%
  • Units of Mutual Funds as permitted by SEBI- 0-10%
  • Units issued by InvITs - 0-10%

Type of scheme

An open ended equity scheme investing in Pharma and Healthcare sector

Stated category
Sectoral/Thematic Fund - Pharma and Healthcare Theme
Benchmark
BSE Healthcare Total Return Index
Second benchmark
Nifty 50 TRI
Risk level at launch
Very high
New fund offer
9 Jun 2025 to 23 Jun 2025
Units first allotted
27 Jun 2025
Open for sale again
1 Jul 2025
Price at the offer
₹10 a unit
Minimum at the offer
₹1,000

Plans and codes

PlanAMFI codeISINISIN, reinvestmentMUTF_INFirst NAV
Direct Growth153604INF251K01VA5BARO_BNP_P_SC1ABA1 Jul 2025
Regular Growth153602INF251K01UY7BARO_BNP_P_3QYJSP1 Jul 2025
Direct IDCW153605INF251K01VB3INF251K01VC1BARO_BNP_P_OWZNFJ1 Jul 2025
Regular IDCW153607INF251K01VD9INF251K01UZ4BARO_BNP_P_17OKL451 Jul 2025

This fund

Factsheet

Statement of additional information

Annual report

Riskometer disclosure

Portfolio overlap disclosure